Apeloa Pharma's Keppra generic gets market nod in China

China-based Apeloa Pharmaceutical Co., Ltd, (000739) announced market approval from the National Medical Products Administration (NMPA) for its generic version of the anti-epilepsy therapy levetiracetam. The market filing for said drug, the company’s first product to pass generic quality consistency evaluation (GQCE) testing, was made in February 2018.

Levetiracetam was originally developed by Belgium-based UCB, marketed under the brand name Keppra, and gained a first global approval in the US in 1999. UCB brought the drug to China in 2006, and it has reportedly generated RMB 1 billion (USD 140 million) in local sales since then.


Related news
Belgium-based UCB has handed over China market promotion rights to its Niferex (iron polysaccharide complex capsules) to Shanghai-based Nuance Biotech Inc., according to Mrclub, a local media platform.
Belgium-based UCB revealed that the firm’s Parkinson’s disease therapy Neupro (rotigotine) launched to market in China, with a first prescription issued on October 17.
  • 1541400213271
  • China
  • Drug
China-based Zhejiang Jingxin Pharmaceutical Co., Ltd (002020.SZ) announced receipt of approval from the National Medical Products Administration (NMPA) for a supplementary application in relation to sertraline hydrochloride tablets, amounting to the completion of generic consistency equivalency (GCE) work for that product.
Shandong Public Resources Trading Center released the first modified provincial centralized procurement drugs list, which marks 7,775 products barred from purchases, 120 with usage limitations, and culls 2,160.
Belgium-basedUCB SAannounced China market approval for the firm's Parkinson's disease (PD) therapy Neupro (rotigotine), a transdermal patch that allows continuous drug delivery for 24 hours.
  • 1530672572884
  • China
  • Drug
Recent news
A study carried out by investigators at Brazil’s Oswaldo Cruz Foundation (Fiocruz) estimated the coping costs for the caretakers of minors with one of three selected rare diseases.
Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) this week ruled that all medical products that contain active pharmaceutical ingredients (APIs) that require bioequivalence tests must submit applications for these studies within 180 days.
Austria-based Themis is set to carry out a Phase III clinical trial (CT) on its chikungunya vaccine candidate.
  • 1568979876836
  • Mexico,Colombia,Guatemala,Dominican Republic,Chile,Puerto Rico ,Nicaragua,Guyana,Brazil,Cuba,Belize,Argentina,Paraguay,Ecuador ,Costa Rica,Peru,El Salvador,Panama,Haiti,Uruguay,Venezuela,Bolivia ,Honduras
  • Drug, Company
China’s leading plasma-based biopharmaceutical company China Biologic Products Holdings Inc., (NASDAQ: CBPO) is once again being targeted by a consortium of investors in a potential USD 4.59 billion buyout deal that would take the firm private.
Suzhou-based biotech CStone Pharmaceuticals (HKEX.2616) announced that the GEMSTONE-101 cohort study for anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb) CS1001 combined with cisplatin plus fluorouracil (CF) therapy in esophagus squamous cell carcinoma (ESCC) has yielded a 77.8% objective response rate (ORR) with good safety.
Shenzhen Chipscreen Biosciences Co., Ltd, (SH.688321) announced acceptance for review from the National Medical Products Administration (NMPA) in relation to a new drug application (NDA) filed for hypoglycemic drug chiglitazar (Bilessglu).
A draft law presented this week to Peru’s unicameral Congress by the New Peru (Nuevo Perú) minority party would force medics to prescribe generic medicines as a primary choice and originator drugs as a second alternative.
Analytics Snapshot

Analytics Snapshot